Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype.

Oncogene - 1 Aug 2018

Kota Smitha, Hou Shurong, Guerrant William, Madoux Franck, Troutman Scott, Fernandez-Vega Virneliz, Alekseeva Nina, Madala Neeharika, Scampavia Louis, Kissil Joseph, Spicer Timothy P

Abstract excerpt

The RAS proteins are the most frequently mutated oncogenes in cancer, with highest frequency found in pancreatic, lung, and colon tumors. Moreover, the activity of RAS is required for the proliferation and/or survival of these tumor cells and thus represents a high-value target for therapeutic development. Direct targeting of RAS has proven challenging for multiple reasons stemming from the biology of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Culture Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Screening Assays, Antitumor

Share to Mutation

Share to Phenotype

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 29743592
DOI: 10.1038/s41388-018-0257-5
PMCID: PMC6138545

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype.PMID 29743592Read ↗

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Semantic proximity Read ↗

Generation of Patient-Derived Colorectal Cancer Organoids for RAS Studies.Semantic proximity Read ↗

Identification of potent Ras signaling inhibitors by pathway-selective phenotype-based screening.Semantic proximity Read ↗

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesSemantic proximity Read ↗

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningSemantic proximity Read ↗

Functional Analysis of Rare RAS Variants of Unknown Significance.Semantic proximity Read ↗

RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics.Semantic proximity Read ↗

Development of small-molecule probes that selectively kill cells induced to express mutant RAS.Semantic proximity Read ↗

Inhibition of Ras for cancer treatment: the search continues.Semantic proximity Read ↗

Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.Semantic proximity Read ↗

Identification of Noncovalent Small-Molecules from Virtual Screening Toward the Development of Potential KRAS Inhibitors.Semantic proximity Read ↗

Discovery of novel indazole derivatives as SOS1 agonists that activate KRAS signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.